Results 31 to 40 of about 110,851 (248)
Frontiers in Endocrinology, 2014 Glycogen synthase kinase-3 (Gsk-3) activity is an important regulator of numerous signal transduction pathways. Gsk-3 activity is the sum of two largely redundant proteins, Gsk-3α and Gsk-3β, and in general, Gsk-3 is a negative regulator of cellular ...
Colleen M Bartman +6 more
doaj +1 more source
A pivotal role of GSK-3 in synaptic plasticity [PDF]
Frontiers in Molecular Neuroscience, 2012 Glycogen synthase kinase-3 (GSK-3) has many cellular functions. Recent evidence suggests that it plays a key role in certain types of synaptic plasticity, in particular a form of long-term depression (LTD) that is induced by the synaptic activation of N-methyl-D-aspartate receptors (NMDARs).
Clarrisa A Bradley +13 more
openaire +4 more sources
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
BMC Cancer, 2010 Background Glycogen Synthase Kinase-3 (GSK-3) α and β are two serine-threonine kinases controlling insulin, Wnt/β-catenin, NF-κB signaling and other cancer-associated transduction pathways.
Colpo Anna +12 more
doaj +1 more source
GSK-3 – at the crossroads of cell death and survival [PDF]
Journal of Cell Science, 2014 ABSTRACT Glycogen synthase kinase 3 (GSK-3) is involved in various signaling pathways controlling metabolism, differentiation and immunity, as well as cell death and survival. GSK-3 targets transcription factors, regulates the activity of metabolic and signaling enzymes, and controls the half-life of proteins by earmarking them for ...
Maurer, Ulrich +4 more
openaire +3 more sources
GSK-3 Inhibitors: Discoveries and Developments
Current Medicinal Chemistry, 2004 Glycogen synthase kinase 3 (GSK-3) in the 21st century emerged as one of the most attractive therapeutic target for the development of selective inhibitors as new promising drugs for unmet pathologies including Alzheimer's disease, stroke, bipolar disorders, chronic inflammatory processes, cancer and diabetes type II.
Mercedes Alonso, Ana Martinez
openaire +2 more sources
Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent. [PDF]
PLoS ONE, 2013 Glycogen synthase kinase-3 (GSK-3) inhibitors have been postulated as useful therapeutic tools for the treatment of chronic neurodegenerative and neuropsychiatric diseases.
Raquel Gómez-Sintes, José J Lucas
doaj +1 more source
Focusing the spotlight on GSK-3 in aging
Aging, 2013 Aging/senescence occurs at both the level of the whole organism and the individual cell. Organismal aging is usually defined as the progressive loss of function accompanied by decreasing fertility and increasing mortality with advancing age [1]. Cellular senescence refers to the permanent arrest of cell division, which is characterized by several ...
Jibin, Zhou, Thomas, Force
openaire +2 more sources
GSK-3 and lysosomes meet in Alzheimer’s disease [PDF]
Communicative & Integrative Biology, 2013 Aberrant regulation of glycogen synthase kinase-3 (GSK-3) is implicated in Alzheimer's disease (AD), but the mechanisms involved remain elusive. Our recent study shows that GSK-3 impairs lysosomal acidification and that inhibition of GSK-3 re-acidified lysosomes in brains of AD mice.
Avrahami, Limor, Eldar-Finkelman, Hagit
openaire +2 more sources
Molecular Oncology, EarlyView.Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch +13 more
wiley +1 more source
AP-1 is a component of the transcriptional network regulated by GSK-3 in quiescent cells. [PDF]
PLoS ONE, 2011 The protein kinase GSK-3 is constitutively active in quiescent cells in the absence of growth factor signaling. Previously, we identified a set of genes that required GSK-3 to maintain their repression during quiescence.
John W Tullai +4 more
doaj +1 more source